Horizon Healthcare (pvt.) ltd.
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical manufacturer · Taxila · Pakistan
Pakistan pharmaceutical manufacturer with a DRAP-listed manufacturing facility in Taxila and a broad branded product portfolio.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Private pharmaceutical manufacturer
- Address
- Plot No. 35-A, Small Industrial Estate, Taxila, Rawalpindi, Pakistan
- Website
- horizonpharma.net.pk ↗
- Corporate source details checked
- 21 Aug 2026
- Corporate profile completeness
- 63%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Horizon Healthcare (pvt.) ltd. is priced against the market
85 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Iromose-F | Iron polymaltose complex + Folic acid | 100 mg + 0.35 mg | Tablet | 30’s | 078741 | PKR 398.61 | PKR 13.29/tablet | 🔒 Pharma Pro |
| Isaac | Voriconazole | 50 mg | Tablet | 10’s | 105871 | PKR 797.88 | PKR 79.79/tablet | 🔒 Pharma Pro |
| Iveetin | Ivermectin | 3 mg | Tablet | 20’s | 115587 | PKR 638.30 | PKR 31.92/tablet | 🔒 Pharma Pro |
| Lacura | Ceftriaxone | 1 g | Injection | 1's | 098043 | PKR 662.97 | PKR 662.97/vial/unit | 🔒 Pharma Pro |
| Lacura | Ceftriaxone | 500 mg | IM injection | 1's | 098044 | PKR 351.10 | PKR 351.10/vial/unit | 🔒 Pharma Pro |
| Lacura | Ceftriaxone | 250 mg | IM injection | 1's | 098045 | PKR 208.59 | PKR 208.59/vial/unit | 🔒 Pharma Pro |
| Lacura | Ceftriaxone | 1 g | Injection | 1's | 098050 | PKR 662.97 | PKR 662.97/vial/unit | 🔒 Pharma Pro |
| Lacura | Ceftriaxone | 500 mg | Injection | 1's | 098051 | PKR 351.10 | PKR 351.10/vial/unit | 🔒 Pharma Pro |
| Lacura | Ceftriaxone | 250 mg | Injection | 1's | 098052 | PKR 208.59 | PKR 208.59/vial/unit | 🔒 Pharma Pro |
| Latanoprost-T | Latanoprost + Timolol | 50 mcg/mL + 5 mg/mL | Ophthalmic solution | 2.5ml | 119400 | PKR 759.13 | PKR 303.65/mL | No comparator |
| Latazon 0.005% w/v Eye | Latanoprost | 0.005 % | Ophthalmic drops | 2.5ml | 119355 | PKR 717.32 | PKR 286.93/mL | 🔒 Pharma Pro |
| Lemit | Levofloxacin | 250 mg | Tablet | 10's | 078745 | PKR 498.68 | PKR 49.87/tablet | 🔒 Pharma Pro |
| Lemit | Levofloxacin | 500 mg | Tablet | 10's | 078746 | PKR 829.80 | PKR 82.98/tablet | 🔒 Pharma Pro |
| Listono | Colistimethate sodium | 1 MIU | Injection | 1's | 119201 | PKR 1,199.81 | PKR 1,199.81/vial/unit | 🔒 Pharma Pro |
| Listono | Colistimethate sodium | 2 MIU | Injection | 1's | 119202 | PKR 2,000.07 | PKR 2,000.07/vial/unit | 🔒 Pharma Pro |
| Listono | Colistimethate sodium | 3 MIU | Injection | 1's | 119203 | PKR 3,000.68 | PKR 3,000.68/vial/unit | 🔒 Pharma Pro |
| Listono | Colistimethate sodium | 4.5 MIU | Injection | 1's | 119204 | PKR 4,501.60 | PKR 4,501.60/vial/unit | 🔒 Pharma Pro |
| Lotfee | Levofloxacin | 250 mg | Tablet | 10's | 105886 | PKR 498.67 | PKR 49.87/tablet | 🔒 Pharma Pro |
| Lotfee | Levofloxacin | 500 mg | Tablet | 10's | 105887 | PKR 829.79 | PKR 82.98/tablet | 🔒 Pharma Pro |
| Mauris | Clopidogrel | 75 mg | Tablet | 10’s | 107323 | PKR 282.13 | PKR 28.21/tablet | 🔒 Pharma Pro |
| Mofoxin | Moxifloxacin | 400 mg | Tablet | 5's | 098063 | PKR 981.02 | PKR 196.20/tablet | 🔒 Pharma Pro |
| Moxidanz | Moxifloxacin | 400 mg | Tablet | 5's | 096423 | PKR 981.02 | PKR 196.20/tablet | 🔒 Pharma Pro |
| Mutrum | Mupirocin | 2% | Ointment | 15gm | 085348 | PKR 219.41 | PKR 14.63/g | 🔒 Pharma Pro |
| Mytodone | Risperidone | 1 mg | Tablet | 10’s | 116689 | PKR 239.36 | PKR 23.94/tablet | 🔒 Pharma Pro |
| Mytodone | Risperidone | 2 mg | Tablet | 10’s | 116690 | PKR 388.97 | PKR 38.90/tablet | 🔒 Pharma Pro |
| Mytodone | Risperidone | 4 mg | Tablet | 10’s | 116692 | PKR 777.93 | PKR 77.79/tablet | 🔒 Pharma Pro |
| Nisol | Methylprednisolone | 40 mg/mL | Injection | 1ml | 085362 | PKR 209.45 | PKR 209.45/mL | No comparator |
| Nomether | Artemether | 80 mg/mL | Injection | 5's x 1ml | 085353 | PKR 957.45 | PKR 191.49/mL | 🔒 Pharma Pro |
| Nomether-L | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 10’s | 116483 | PKR 618.36 | PKR 61.84/tablet | 🔒 Pharma Pro |
| Nomether-L | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 8’s | 116484 | PKR 658.25 | PKR 82.28/tablet | 🔒 Pharma Pro |
| O-Monix | Ondansetron | 4 mg/5 mL | Oral solution | 50ml | 119281 | PKR 997.35 | PKR 19.95/mL | 🔒 Pharma Pro |
| Orsini | Linezolid | 600 mg | Tablet | 12's | 096424 | PKR 4,659.32 | PKR 388.28/tablet | 🔒 Pharma Pro |
| P-Bru 500/200mg TabletRegistry verified | Paracetamol …………500mg Ibuprofen ………… .200mg | — | — | — | 136995Official source ↗ | No indexed price | — | — |
| Penviro 1% w/w CreamRegistry verified | Penciclovir | — | — | — | 135675Official source ↗ | No indexed price | — | — |
| Phenomi | Clomifene citrate | 50 mg | Tablet | 10's | 099980 | PKR 446.11 | PKR 44.61/tablet | 🔒 Pharma Pro |
| Premexo-XR 165mg TabletRegistry verified | Pregabalin | — | — | — | 136992Official source ↗ | No indexed price | — | — |
| Premexo-XR 330mg TabletRegistry verified | Pregabalin | — | — | — | 136993Official source ↗ | No indexed price | — | — |
| Premexo-XR 82.5mg TabletRegistry verified | Pregabalin | — | — | — | 136991Official source ↗ | No indexed price | — | — |
| Prestia | Methylprednisolone | 40 mg | Injection | 1's | 094190 | PKR 209.45 | PKR 209.45/vial/unit | 🔒 Pharma Pro |
| Prestia | Methylprednisolone | 125 mg | Injection | 1's | 094191 | PKR 323.14 | PKR 323.14/vial/unit | 🔒 Pharma Pro |
| Prestia | Methylprednisolone | 500 mg | IV/IM injection | 1's | 119205 | PKR 1,773.29 | PKR 1,773.29/vial/unit | No comparator |
| Prestia | Methylprednisolone | 1 g | Injection | 1's | 119206 | PKR 2,954.15 | PKR 2,954.15/vial/unit | 🔒 Pharma Pro |
| Ramacin | Azithromycin | 250 mg | Capsule | 10’s | 078737 | PKR 519.23 | PKR 51.92/capsule | 🔒 Pharma Pro |
| Ramacin | Azithromycin | 500 mg | Tablet | 6's | 100845 | PKR 567.96 | PKR 94.66/tablet | 🔒 Pharma Pro |
| Retinib 50mg CapsuleRegistry verified | Ritlecitinib (equivalent to 80.13 mg Ritlecitinib tosylate) | — | — | — | 136849Official source ↗ | No indexed price | — | — |
| Retirom 100mg tabletRegistry verified | Resmetirom | — | — | — | 136842Official source ↗ | No indexed price | — | — |
| Retirom 60mg TabletRegistry verified | Resmetirom | — | — | — | 136840Official source ↗ | No indexed price | — | — |
| Retirom 80mg TabletRegistry verified | Resmetirom | — | — | — | 136841Official source ↗ | No indexed price | — | — |
| Ritolo 200 | Lopinavir + Ritonavir | 200 mg + 50 mg | Tablet | 120's | 102267 | PKR 15,861.53 | PKR 132.18/tablet | 🔒 Pharma Pro |
| Sedobet | Betamethasone | 0.05% | Cream | 15gm | 085349 | PKR 59.85 | PKR 3.99/g | 🔒 Pharma Pro |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.